ClinicalTrials.gg
Active, not recruitingNCT07577141VENOUS-TKAUpdated Oct 15, 2026

Impact of Chronic Venous Insufficiency on Outcomes After Total Knee Arthroplasty

An observational study in Total Knee Anthroplasty, Venous Insufficiency (Chronic)(Peripheral) and Doppler Ultrasound Diagnosis, sponsored by SB Istanbul Education and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by SB Istanbul Education and Research Hospital · Observational

Updated Oct 15, 2026Now Active, not recruitingFirst site in Turkey (Türkiye)+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Total knee arthroplasty (TKA) is an effective treatment for end-stage knee osteoarthritis; however, postoperative complications-particularly wound healing problems-remain a significant concern. Chronic venous insufficiency (CVI) is associated with venous hypertension, impaired microcirculation, and tissue hypoxia, which may negatively affect wound healing and increase complication rates.

This prospective observational cohort study aims to evaluate the impact of preoperative CVI on postoperative outcomes following TKA. Patients will be assessed preoperatively using the CEAP classification and Doppler ultrasonography to identify and stratify venous insufficiency.

Participants will be followed for 12 months postoperatively. The primary outcome will be wound healing complications in the early postoperative period. Secondary outcomes will include functional outcomes assessed by the Knee Society Score (KSS), patient-reported outcomes using the WOMAC score, and overall complication rates.

The findings of this study are expected to clarify the role of venous insufficiency as a potential risk factor in TKA and may contribute to improved preoperative risk stratification and postoperative management strategies.

Read the detailed description

Total knee arthroplasty (TKA) is a highly successful surgical intervention for the treatment of end-stage knee osteoarthritis, providing significant pain relief and functional improvement. Despite advances in surgical techniques and perioperative care, postoperative complications-particularly wound healing problems and surgical site infections-remain clinically relevant and may adversely affect patient outcomes.

Chronic venous insufficiency (CVI) is a common vascular condition characterized by venous reflux, venous hypertension, and impaired microcirculation. These pathophysiological changes may lead to tissue edema, reduced oxygenation, and delayed wound healing. Although CVI has been associated with impaired soft tissue healing in various clinical settings, its impact on postoperative outcomes following TKA has not been clearly defined.

The aim of this prospective observational cohort study is to investigate the effect of preoperative CVI on wound healing, functional outcomes, and complication rates after primary TKA. Preoperatively, all patients will undergo a standardized venous assessment including clinical classification using the CEAP system and Doppler ultrasonography to evaluate venous reflux, vein diameter, and the anatomical distribution of insufficiency. Based on these assessments, patients will be stratified into CVI and non-CVI groups.

All procedures will be performed using a standardized surgical technique for primary TKA. Perioperative variables such as operative time, tourniquet use, and comorbidities will be recorded to control for potential confounders.

Postoperative follow-up will be conducted at regular intervals, including early wound assessment at 2 weeks and subsequent evaluations at 6 weeks, 3 months, 6 months, and 12 months. The primary outcome of the study will be wound healing complications in the early postoperative period, including delayed wound healing, wound dehiscence, and surgical site infections. Secondary outcomes will include functional outcomes measured by the Knee Society Score (KSS), patient-reported outcomes assessed by the WOMAC score, length of hospital stay, and overall complication rates.

Statistical analysis will include comparative analyses between groups and multivariate regression models to determine whether CVI is an independent predictor of postoperative complications and functional outcomes. The severity of venous insufficiency, as classified by CEAP, will also be analyzed in relation to clinical outcomes.

This study is expected to provide clinically relevant evidence regarding the role of CVI in TKA outcomes. Identifying CVI as a potential risk factor may improve preoperative risk stratification, guide perioperative management, and ultimately enhance patient outcomes following total knee arthroplasty.

02

Conditions studied

  • Total Knee Anthroplasty
  • Venous Insufficiency (Chronic)(Peripheral)
  • Doppler Ultrasound Diagnosis

Keywords

  • total knee arthroplasty
  • chronic venous insufficiency
  • doppler
  • wound
03

In context

Venous Insufficiency

162 studies on the registry are indexed under Venous Insufficiency; 14 are open to participants now.

This study's planned enrollment of 100 is close to the median of 91 across 28 observational studies indexed under Venous Insufficiency.

Browse Venous Insufficiency studies →

Lead sponsor

SB Istanbul Education and Research Hospital is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Total Knee Arthroplasty patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing primary total knee arthroplasty
  • Age ≥ 50 years
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Revision TKA
  • Peripheral arterial disease (ABI \< 0.9)
  • Active infection
  • History of deep vein thrombosis within 6 months
  • therapy
  • Severe uncontrolled diabetes mellitus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • CVI Group

    Patients with chronic venous insufficiency (CEAP + Doppler confirmed)

  • Non-CVI Group

    Patients without chronic venous insufficiency on clinical and Doppler evaluation

06

What researchers measure

Primary outcomes

  1. Wound healing complications

    Delayed healing Wound dehiscence Superficial/deep infection

    Time frame: Preoperative baseline Postoperative: 2 weeks (wound assessment)

Secondary outcomes

  1. WOMAC score

    WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): The WOMAC score ranges from 0 to 96 (or 0 to 100 depending on the version used), with higher scores indicating worse pain, stiffness, and functional limitation.

    Time frame: Preoperative baseline Postoperative: 6 weeks 6 months 12 months

  2. KNEE SOCIETY SCORE

    KSS (Knee Society Score): The Knee Society Score ranges from 0 to 100, with higher scores indicating better knee function and clinical outcome, whereas lower scores reflect poorer function and increased symptoms.

    Time frame: Preoperative Postoperative 6th week Postoperative 6th month Postoperative 12nd month

07

Study locations

1 site
  • İstanbul Educaiton and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Publications

  • Summers S, Yakkanti R, Ocksrider J, Haziza S, Mannino A, Roche M, Hernandez VH. Effects of Venous Insufficiency in Patients Undergoing Primary Total Knee Arthroplasty: An Analysis of 1.2 Million Patients. J Knee Surg. 2023 Feb;36(3):322-328. doi: 10.1055/s-0041-1733901. Epub 2021 Aug 31. PubMed 34464986 ↗
  • Cansabuncu G, Gumus F. Pre-operative predictors of lower extremity swelling following total knee arthroplasty in patients with venous insufficiency and osteoarthritis. Int Orthop. 2021 Oct;45(10):2561-2567. doi: 10.1007/s00264-020-04888-0. Epub 2021 Jan 7. PubMed 33409562 ↗
  • Robin KJ, Maier MA, Leslie LJ, Dasa V, Krause PC, Jones DG, Chapple AG. Severity of Chronic Venous Insufficiency on Primary Total Knee Arthroplasty Outcomes. J Arthroplasty. 2023 Nov;38(11):2324-2327.e4. doi: 10.1016/j.arth.2023.05.040. Epub 2023 Jun 5. PubMed 37286057 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to patient privacy and confidentiality considerations. The dataset contains clinical and imaging information collected within a single-center observational study. In accordance with institutional ethics committee regulations and data protection policies, sharing of individual-level data with external parties is not planned.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 11, 2026
StartActual
Jun 30, 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • İstanbul Educaiton and Research Hospital · Istanbul, Turkey (Türkiye)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • İstanbul Educaiton and Research Hospital · Istanbul, Turkey (Türkiye)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577141
Lead sponsor
SB Istanbul Education and Research Hospital
Responsible party
Baris Acar (Assistant Proffesor, SB Istanbul Education and Research Hospital) — Principal investigator
First posted
May 11, 2026
Start date
Jun 30, 2026
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion